Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway
Pharmaceuticals · 29.05.2026 · 19 (6) · 864
DOI: 10.3390/ph19060864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 29.05.2026. Verfasst von Qingmeng Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province, Project of Education Department of Liaoning Province, National Undergraduate Innovation and Entrepreneurship Training Project.
Abstract (Originalsprache)
Objectives
This study aims to investigate the pharmacological effects and potential mechanisms of dehydrocorydaline, the primary active component of Corydalis yanhusuo W.T. Wang, as a potential therapeutic agent for pancreatic cancer, thereby providing new insights into its treatment.
Methods
The pharmacological effects were assessed through MTT assay, colony formation assay, flow cytometry, scratch wound assay, and transwell assay. Potential mechanisms were explored through bioinformatics analysis and Western blot.
Results
Dehydrocorydaline was verified to stimulate apoptosis and inhibit the growth, migration, and invasion of pancreatic cancer BxPC-3 cells. These effects may be associated with suppressed HSP90α expression, induced ERBB2 degradation, and subsequent inhibition of STAT3 and PI3K/Akt/mTOR pathway activation, as well as altered expression of multiple downstream proteins.
Conclusions
This study demonstrates that dehydrocorydaline is the main active component of Corydalis yanhusuo W.T. Wang with anti-pancreatic cancer activity. Based on protein expression-level evidence, it may exert its effects by inhibiting HSP90α expression and inducing ERBB2 degradation, thereby affecting the PI3K/Akt/mTOR and STAT3 pathways, ultimately suppressing proliferation, migration, and invasion while promoting apoptosis in BxPC-3 cells. These findings justify further investigation of dehydrocorydaline as a potential treatment for pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
- School of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang 110016, China.
Förderung
- Natural Science Foundation of Liaoning Province
- Project of Education Department of Liaoning Province
- National Undergraduate Innovation and Entrepreneurship Training Project
Zitieren
APA
Yu, Q., Li, R., Li, Z., Wan, Z., Lv, K., He, C., Sun, J., Jia, S., Xu, Y., & Zhao, M. (2026). Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway. Pharmaceuticals, 19(6), 864. https://doi.org/10.3390/ph19060864
Vancouver
Yu Q, Li R, Li Z, Wan Z, Lv K, He C, et al. Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway. Pharmaceuticals. 2026;19(6):864. doi:10.3390/ph19060864
BibTeX
@article{Yu2026,
author = {Yu, Qingmeng and Li, Ruiding and Li, Zhengyu and Wan, Zhexin and Lv, Kaikai and He, Chongyang and Sun, Jianfang and Jia, Shubing and Xu, Yijia and Zhao, Mingyi},
title = {Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {6},
pages = {864},
doi = {10.3390/ph19060864}
}
EUVIMED